PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
6174521-2	1982	Glycopeptides and oligosaccharides were prepared from alpha-fetoprotein by protease treatment and hydrazinolysis, respectively, and subjected to carbohydrate and amino acid analysis.	Glycopeptides	0-13	alpha fetoprotein	Homo sapiens	54-71	
32786443-10	2020	To the best of our knowledge, this is the first report of the AQUA of N-glycosylated AFP in human sera using a stable isotope-labeled glycopeptide as an internal standard.	Glycopeptides	134-146	alpha fetoprotein	Homo sapiens	85-88	
28323416-3	2017	As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.	Glycopeptides	146-159	alpha fetoprotein	Homo sapiens	19-36	
28323416-3	2017	As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.	Glycopeptides	146-159	alpha fetoprotein	Homo sapiens	38-41	
28323416-3	2017	As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.	Glycopeptides	146-158	alpha fetoprotein	Homo sapiens	19-36	
28323416-3	2017	As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.	Glycopeptides	146-158	alpha fetoprotein	Homo sapiens	38-41	
28323416-3	2017	As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.	Glycopeptides	257-270	alpha fetoprotein	Homo sapiens	38-41	
28323416-3	2017	As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.	Glycopeptides	257-270	alpha fetoprotein	Homo sapiens	38-41	
33929864-6	2021	When combining results of these 2 glycopeptides with AFP, the ROC curve analysis demonstrated the AUC value increased to 0.834 (95% CI, 0.748-0.921) and 0.847 (95% CI, 0.766-0.932), respectively, as compared to that of AFP alone (AUC = 0.791, 95% CI, 0.690-0.892).	Glycopeptides	34-47	alpha fetoprotein	Homo sapiens	219-222	
33889548-8	2021	Among them, glycopeptides from APOH, HPT/HPTR, and PON1 were significantly changed in AFP-negative HCC as compared to LC.	Glycopeptides	12-25	alpha fetoprotein	Homo sapiens	86-89	
33889548-10	2021	The two glycopeptides HAN253WTLTPLK (H5N4S2) and (H5N4S1) corresponding to PON1 were significantly increased in AFP-negative HCC patients, as compared with LC patients.	Glycopeptides	8-21	alpha fetoprotein	Homo sapiens	112-115